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The iron-chelating drug M30 down-regulates carbon tetrachloride (CCl4)-induced 
hepatic oxidative stress, inflammation and apoptosis in vitro 
 
Rui Guo
1
, Jia Xiao
1,2
, Jing Fei Pan
3
, Emily C. Liong
1
, Man Lung Fung
3,4
, Kwok Fai So
1,4
, 
Moussa Youdim
5
, Bin Lin
1,4
, George L. Tipoe
1,4
 
1
Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong 
Kong S.A.R., 
2
Center for Gene and Cell Engineering, Shenzhen Institute of Advanced 
Technology, Chinese Academy of Sciences, Shenzhen, China, 
3
Physiology, 
4
Brain 
Hormone Healthy Aging Centre, LKS Faculty of Medicine, The University of Hong 
Kong, Hong Kong, Hong Kong S.A.R., 
5
Faculty of Medicine, Technion-Israel Institute of 
Technology, Haifa, Israel 
 
BACKGROUND/AIMS: The novel multifunctional brain permeable ironchelator M30 
possesses neuroprotective activities against several insults applicable to various 
neurodegenerative diseases. However, the effect of M30 on CCl4 induced acute liver 
damage is still unknown. The aim of this study is to investigate whether the 
multifunctional drug M30 could ameliorate CCl4 induced hepatic injury in human 
HepG2 cell line. METHODS: HepG2 cells were grown in DMEM supplemented with 
10 %fetal bovine serum and they were divided into control, CCl4, M30, and CCl4 + M30 
co-treatment groups. M30 was pretreated for 2 h containing a final concentration at 5 lM. 
Then CCl4 was added with a final concentration at 2 ll/ml and incubated for 1 h. Finally, 
the cells were harvested and the cell viability was determined by colorimetric MTT assay 
based on conversion of MTT to blue formazan crystals by viable cells. In addition, the 
malondialdehyde levels were determined using a Bioxytech LPO-586TM kit, and real 
time PCR was also utilized to test the RNA expression levels of antioxidant enzymes, 
pro-inflammatory mediators and apoptotic markers. RESULTS: M30 significantly 
reduced CCl4 triggered cell death and MDA levels. Co-treatment of M30 and CCl4 up-
regulated the expression levels of antioxidant enzymes catalase and glutathione 
peroxidase, which indicated that M30 reduced CCl4-induced oxidative stress and 
inhibited lipid peroxidation. In addition, administration of M30 attenuated hepatic 
inflammation triggered by CCl4 via inhibiting pro-inflammatory mediators, such as 
tumor necrosis factor alpha and interleukin-6. M30 also exhibited its anti-apoptotic 
activity by downregulating proapoptotic protein Bax, up-regulating anti-apoptotic protein 
Bcl-XL, as well as by recruiting Fas-associated death domain (FADD). CONCLUSION: 
M30 attenuates CCl4-induced HepG2 cellular damage through its antioxidant, anti-
inflammatory and anti-apoptotic properties, which could serve as a potential functional 
drug to treat acute hepatotoxicity and chronic liver diseases such as non-alcoholic fatty 
liver disease and steatohepatitis. 
